Navigating HER2+ Breast Cancer Treatment: A Patient's Journey

November 18, 2024

By Neil M. Iyengar, MD
Odessa Williams, NP, ANCC

Opinion

Video

Panelists discuss how a patient navigated her treatment journey at Memorial Sloan Kettering (MSK), detailing the specific treatments received, her responses to those treatments, and her active participation in the shared decision-making process regarding her care.

EP: 1.Overview of HER2 Breast Cancer

EP: 2.HER2+ Breast Cancer Diagnosis: Insights From Patients and Clinicians

EP: 3.Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach

EP: 4.Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective

EP: 5.Tailoring Patient Education and Resources in HER2+ Breast Cancer

Now Viewing

EP: 6.Navigating HER2+ Breast Cancer Treatment: A Patient's Journey

EP: 7.Navigating Systemic Therapy Options in HER2+ Breast Cancer

EP: 8.Key Insights from the HER2CLIMB Trial

EP: 9.Key Insights From the DEBBRAH and HER2CLIMB-02 Studies

EP: 10.BRIDGET Trial: Strategies in Maintenance Therapy for HER2+ Breast Cancer with Brain Metastases

EP: 11.Preparing Patients for Treatment: Education, Administration and Adverse Effect Management in HER2+ Breast Cancer

EP: 12.Patient Perspectives on Managing Adverse Effects from Capecitabine, Trastuzumab, and Tucatinib

EP: 13.Comprehensive Supportive Care for Metastatic HER2+ Breast Cancer

EP: 14.Patient Perspective: Key Aspects of Supportive Care in the HER2+ Breast Cancer Journey

EP: 15.Future Perspectives in HER2+ Breast Cancer

EP: 16.Closing Thoughts: Key Messages for Clinicians and Patients in the Treatment of HER2+ Breast Cancer

EP: 17.Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective

Dr Iyengar asks Dorian Nygard: Dorian, can you walk us through your treatment journey at MSK?
1. What specific treatments did you receive and how did you respond
2. How did you participate in the shared decision-making process for your treatment?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!